Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CAR T-Cell Therapy
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Generate Biomedicines
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 01, 2023
Lead Product(s) : CAR T-Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Generate Biomedicines
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rintatolimod,Interferon Alfa-2B,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Aim ImmunoTech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has demonstrated in the clinic the potential for standalone efficacy in a number of solid tumors.
Brand Name : Ampligen
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 14, 2022
Lead Product(s) : Rintatolimod,Interferon Alfa-2B,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Aim ImmunoTech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rintatolimod,Interferon Alfa-2B,Celecoxib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Aim ImmunoTech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ampligen (rintatolimod) is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
Brand Name : Ampligen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 30, 2022
Lead Product(s) : Rintatolimod,Interferon Alfa-2B,Celecoxib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Aim ImmunoTech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rintatolimod,Celecoxib,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Aim ImmunoTech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data, from a small number of subjects, is extremely impressive for four out of six Ampligen plus pembrolizumab patients; three demonstrated disease stabilization and one showed a significant and dramatic rapid destruction of the tumor and metastasis.
Brand Name : Ampligen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2022
Lead Product(s) : Rintatolimod,Celecoxib,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Aim ImmunoTech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rintatolimod,Celecoxib,Recombinant Interferon Alfa-2b
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Aim ImmunoTech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Primary endpoint of the study was met for Ampligen (rintatolimod), selective TLR3 ligand, evidenced by increased CD8a expression post-treatment (p=0.046), as a component of treatment for colorectal cancer metastatic to the liver.
Brand Name : Ampligen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2022
Lead Product(s) : Rintatolimod,Celecoxib,Recombinant Interferon Alfa-2b
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Aim ImmunoTech
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?